Whole‐exome sequencing of T‐B+ severe combined immunodeficiency in Egyptian infants, JAK3 predominance and novel variants. (2nd November 2020)
- Record Type:
- Journal Article
- Title:
- Whole‐exome sequencing of T‐B+ severe combined immunodeficiency in Egyptian infants, JAK3 predominance and novel variants. (2nd November 2020)
- Main Title:
- Whole‐exome sequencing of T‐B+ severe combined immunodeficiency in Egyptian infants, JAK3 predominance and novel variants
- Authors:
- El Hawary, R.
Meshaal, S.
Mauracher, A.A.
Opitz, L.
Abd Elaziz, D.
Lotfy, S.
Eldash, A.
Boutros, J.
Galal, N.
Pachlopnik Schmid, J.
Elmarsafy, A. - Abstract:
- Summary: Severe combined immunodeficiency (SCID) is fatal if not treated with immune reconstitution. In Egypt, T ‐ B + SCID accounts for 38·5% of SCID diagnoses. An accurate genetic diagnosis is essential for choosing appropriate treatment modalities and for offering genetic counseling to the patient's family. The objectives of this study were to describe the clinical, immunological and molecular characteristics of a cohort of twenty Egyptian patients with T ‐ B + SCID. The initial diagnosis (based on clinical features and flow cytometry) was followed by molecular investigation (whole‐exome sequencing). All patients had the classic clinical picture for SCID, including failure to thrive ( n = 20), oral candidiasis ( n = 17), persistent diarrhea ( n = 14), pneumonia ( n = 13), napkin dermatitis ( n = 10), skin rash ( n = 7), otitis media ( n = 3) and meningitis ( n = 2). The onset of manifestations was at the age of 2·4 ± 1·6 months and diagnosis at the age of 6·7 ± ·5 months, giving a diagnostic delay of 4·3 months. JAK 3 gene variants were most frequent ( n = 12) with three novel variants identified, followed by IL2R γ variants ( n = 6) with two novel variants. IL7Rα and CD3ε variants were found once, with a novel variant each. T ‐ B + NK − SCID accounted for approximately 90% of the Egyptian patients with T ‐ B + SCID. Of these T ‐ B + NK − SCID cases, 60% were autosomal recessive syndromes caused by JAK3 mutations and 30% were X‐linked syndromes. It might beSummary: Severe combined immunodeficiency (SCID) is fatal if not treated with immune reconstitution. In Egypt, T ‐ B + SCID accounts for 38·5% of SCID diagnoses. An accurate genetic diagnosis is essential for choosing appropriate treatment modalities and for offering genetic counseling to the patient's family. The objectives of this study were to describe the clinical, immunological and molecular characteristics of a cohort of twenty Egyptian patients with T ‐ B + SCID. The initial diagnosis (based on clinical features and flow cytometry) was followed by molecular investigation (whole‐exome sequencing). All patients had the classic clinical picture for SCID, including failure to thrive ( n = 20), oral candidiasis ( n = 17), persistent diarrhea ( n = 14), pneumonia ( n = 13), napkin dermatitis ( n = 10), skin rash ( n = 7), otitis media ( n = 3) and meningitis ( n = 2). The onset of manifestations was at the age of 2·4 ± 1·6 months and diagnosis at the age of 6·7 ± ·5 months, giving a diagnostic delay of 4·3 months. JAK 3 gene variants were most frequent ( n = 12) with three novel variants identified, followed by IL2R γ variants ( n = 6) with two novel variants. IL7Rα and CD3ε variants were found once, with a novel variant each. T ‐ B + NK − SCID accounted for approximately 90% of the Egyptian patients with T ‐ B + SCID. Of these T ‐ B + NK − SCID cases, 60% were autosomal recessive syndromes caused by JAK3 mutations and 30% were X‐linked syndromes. It might be useful to sequence the JAK3 gene (i.e. targeted Sanger sequencing) in all T ‐ B + SCID patients, especially after X‐linked SCID has been ruled out. Hence, no more than 10% of T ‐ B + SCID patients might require next‐generation for a molecular diagnosis. Abstract : The clinical manifestations in the T ‐ B + SCID patients includes failure to thrive, oral candidiasis, diarrhea, pneumonia, napkin dermatitis, skin rash, otitis media and meningitis. Genetic analysis of T ‐ B + Egyptian SCID patients revealed variants in JAK3 gene in 60% of the patients, IL2RG in 30%, IL7RA in 5% and CD3E in 5%. JAK3 gene should be sequenced in all T ‐ B + patients especially if X SCID is ruled out in male patients by analyzing the family's pedigree, medical history and Sanger sequencing. … (more)
- Is Part Of:
- Clinical and experimental immunology. Volume 203:Number 3(2021)
- Journal:
- Clinical and experimental immunology
- Issue:
- Volume 203:Number 3(2021)
- Issue Display:
- Volume 203, Issue 3 (2021)
- Year:
- 2021
- Volume:
- 203
- Issue:
- 3
- Issue Sort Value:
- 2021-0203-0003-0000
- Page Start:
- 448
- Page End:
- 457
- Publication Date:
- 2020-11-02
- Subjects:
- IL2Rγ -- JAK3 -- severe combined immunodeficiency -- T‐B+SCID -- whole‐exome sequencing
Immunopathology -- Periodicals
616.079 - Journal URLs:
- http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1365-2249 ↗
https://academic.oup.com/cei ↗
http://onlinelibrary.wiley.com/ ↗ - DOI:
- 10.1111/cei.13536 ↗
- Languages:
- English
- ISSNs:
- 0009-9104
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3286.251000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 22033.xml